Novozymes As B Stock Total Debt
| NVZMF Stock | USD 57.14 1.36 2.32% |
Novozymes AS B fundamentals help investors to digest information that contributes to Novozymes' financial success or failures. It also enables traders to predict the movement of Novozymes Pink Sheet. The fundamental analysis module provides a way to measure Novozymes' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novozymes pink sheet.
Novozymes |
Novozymes AS B Company Total Debt Analysis
Novozymes' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Novozymes Total Debt | 7.31 B |
Most of Novozymes' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novozymes AS B is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Novozymes AS B has a Total Debt of 7.31 B. This is 253.85% higher than that of the Basic Materials sector and 213.52% higher than that of the Specialty Chemicals industry. The total debt for all United States stocks is 37.48% lower than that of the firm.
Novozymes Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novozymes' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Novozymes could also be used in its relative valuation, which is a method of valuing Novozymes by comparing valuation metrics of similar companies.Novozymes is currently under evaluation in total debt category among its peers.
Novozymes Fundamentals
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 14.47 B | |||
| Shares Outstanding | 222.86 M | |||
| Shares Owned By Insiders | 8.04 % | |||
| Shares Owned By Institutions | 42.30 % | |||
| Price To Earning | 33.38 X | |||
| Price To Book | 6.19 X | |||
| Price To Sales | 0.82 X | |||
| Revenue | 17.55 B | |||
| Gross Profit | 9.59 B | |||
| EBITDA | 6.12 B | |||
| Net Income | 3.68 B | |||
| Cash And Equivalents | 1.01 B | |||
| Cash Per Share | 3.67 X | |||
| Total Debt | 7.31 B | |||
| Debt To Equity | 0.58 % | |||
| Current Ratio | 1.20 X | |||
| Book Value Per Share | 50.02 X | |||
| Cash Flow From Operations | 4.01 B | |||
| Earnings Per Share | 1.90 X | |||
| Price To Earnings To Growth | 3.85 X | |||
| Target Price | 28.3 | |||
| Number Of Employees | 6.44 K | |||
| Beta | 0.4 | |||
| Market Capitalization | 13.95 B | |||
| Total Asset | 27.98 B | |||
| Retained Earnings | 9.99 B | |||
| Working Capital | 2.67 B | |||
| Current Asset | 6.08 B | |||
| Current Liabilities | 3.41 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 1.38 % | |||
| Net Asset | 27.98 B | |||
| Last Dividend Paid | 6.0 |
About Novozymes Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novozymes AS B's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novozymes using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novozymes AS B based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Novozymes Pink Sheet
Novozymes financial ratios help investors to determine whether Novozymes Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novozymes with respect to the benefits of owning Novozymes security.